- Home
- RGNX vs ALT Comparison
RGNX vs ALT Comparison
Compare RGNX & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGNX | ALT |
|---|---|---|
| Founded | 2008 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.1M | 415.3M |
| IPO Year | 2015 | 2005 |
Fundamental Metrics
Financial Performance| Metric | RGNX | ALT |
|---|---|---|
| Price | $8.61 | $3.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $28.75 | $17.67 |
| AVG Volume (30 Days) | 752.0K | ★ 3.2M |
| Earning Date | 05-11-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.08 | ★ 25.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,393,000.00 | $41,000.00 |
| Revenue This Year | $50.05 | N/A |
| Revenue Next Year | $23.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 126.48 | 105.00 |
| 52 Week Low | $5.04 | $2.87 |
| 52 Week High | $16.19 | $7.73 |
Technical Indicators
Market Signals| Indicator | RGNX | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 48.67 | 36.04 |
| Support Level | $7.81 | $2.91 |
| Resistance Level | $9.28 | $4.25 |
| Average True Range (ATR) | 0.48 | 0.17 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 67.76 | 29.17 |
Price Performance
Historical ComparisonAbout RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.